VEGFR-3-IN-1

CAS No. 2756668-73-0

VEGFR-3-IN-1( —— )

Catalog No. M36479 CAS No. 2756668-73-0

VEGFR-3-IN-1 is a novel, potent, and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 73 Get Quote
5MG 107 Get Quote
10MG 180 Get Quote
25MG 348 Get Quote
50MG 569 Get Quote
100MG 894 Get Quote
500MG 1782 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    VEGFR-3-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    VEGFR-3-IN-1 is a novel, potent, and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.
  • Description
    VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth.
  • In Vitro
    VEGFR-3-IN-1 (compound 38k) exhibits a significantly higher antiproliferative activity on MDA-MB-231 and MDA-MB-436 cells than 10 (IC50 > 50 μM), with IC50 values of 2.22 and 3.50 μM, respectively.VEGFR-3-IN-1 markedly suppresses the phosphorylation of VEGFR3 and its downstream proteins in a dose-dependent manner.Cell Viability Assay Cell Line:MDA-MB-231 and MDA-MB-436 cells Concentration:100 nM Incubation Time:48 hours Result: Exerted antimigration and antiproliferative activities through targeting VEGFR3 in MDA-MB-231 and MDA-MB-436 cells.Western Blot Analysis Cell Line:HDLEC cells Concentration:10-500 nM Incubation Time:Result: Antilymphangiogenic activities of VEGFR-3-IN-1 by suppressing the expression of VEGFR3.
  • In Vivo
    VEGFR-3-IN-1 (50, 25 mg/kg; p.o.) reduces the tumor volume, and displays the strongest inhibitory activity in mice, with a growth inhibition rate of 61.9%.VEGFR-3-IN-1 (10 mg/kg; p.o.) treatment shows the Cmax, AUC0-t , AUC0-∞ and t1/2 values of 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.Animal Model:Nude mice (carrying xenografted BC)Dosage:50 mg/kgAdministration:P.o.;once Result:Reduced the tumor volume, and displayed the strongest inhibitory activity in mice.Animal Model:Sprague-Dawley (SD) rats Dosage:10 mg/kg Administration:P.o. (Pharmacokinetic Analysis)Result:The Cmax, AUC0-t , AUC0-∞ and t1/2 were 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2756668-73-0
  • Formula Weight
    616.1
  • Molecular Formula
    C29H29ClF3N7OS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 12.5 mg/mL (20.29 mM; ultrasonic and warming and adjust pH to 6 with HCl and heat to 60°C )
  • SMILES
    C(NC1=CC(C(F)(F)F)=C(Cl)C=C1)(=O)N2CCN(C3=C4C(SC(=C4)C5=CC=C(C=C5)N6CCN(C)CC6)=NC=N3)CC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li Y, Yang G, et al. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem. 2021;64(16):12022-12048.?
molnova catalog
related products
  • Bevacizumab

    Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.

  • Semaxinib

    Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor.

  • SCR-1481B1

    SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor.